Pharma News

narcotic

CBD: Narcotic substance or a novel food product?

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.
compliance for medical cannabis

Ensuring regulatory compliance for Medical Cannabis

Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.
medical application of CBD, covid

COVID is shifting the conversation about the medical application of CBD

Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.
CBD in the UK, dose

A comprehensive guide to CBD in the UK

Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.
next big pandemic

Antimicrobial resistance: The next big pandemic?

Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Quality of medicinal cannabis, purely plant

Ensuring a high and reproducible quality of medicinal cannabis

Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
series B equity financing, mile high

MHL Series B equity financing and global CPG partnerships

Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
import of medical cannabis, drug

The import of medical cannabis: Germany and the Netherlands

Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.
drug testing

Stop drug testing and start impairment testing

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.
New antibiotics

Finding new antibiotics: The genome way

Professor Tilmann Weber discusses how microbial genomics helps to find the next generation of antibiotics in the race against antimicrobial resistance.
what is cbd, savage cabbage

What is CBD and how does it work?

Savage Cabbage Ltd offer their expertise to explain what cannabidiol (CBD) is and how it works: Read on to find out their perspective.
CBD novel food applications

The European Commission’s ‘pause’ on CBD novel food applications

Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
chronic pain diseases, cannabinoids

Chronic pain diseases and medical cannabis

Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.
THC in CBD, EUMCA

EUMCA: Limit of 0.2% THC in CBD products should not change

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.
medical cannabis

How are different types of medical cannabis working for different diseases?

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.
pain medicine

How cannabinoids can be used as pain medicine

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.
access to medicinal cannabis, trevor jones

The EUMCA: Pioneering access to medicinal cannabis

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
cannabinoid research

Expanding the portfolio of rigorous cannabinoid research with new funding opportunities

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Greenheart CBD

Greenheart CBD: A green crop from seed to shelf

Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
attracting major investors, medicine

Attracting major investors: GreenLight on the international stage

In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.

Follow Open Access Government

Related Special Reports

Related eBooks